Johnson & Johnson Seeks U.S. FDA Approval for Subcutaneous Induction Regimen of Tremfya in Ulcerative Colitis, a First for an IL-23 Inhibitor
November 23, 2024
November 23, 2024
NEW BRUNSWICK, New Jersey, Nov. 23 -- Johnson and Johnson issued the following news release:
* * *
Following recent U.S. FDA approval of TREMFYA for adults with moderately to severely active ulcerative colitis (UC), this submission underscores its potential to be the only IL-23 inhibitor that offers choice of subcutaneous or intravenous induction in UC
Submission is supported by the Phase 3 ASTRO study, which achieved the primary endpoint of clinical remiss . . .
* * *
Following recent U.S. FDA approval of TREMFYA for adults with moderately to severely active ulcerative colitis (UC), this submission underscores its potential to be the only IL-23 inhibitor that offers choice of subcutaneous or intravenous induction in UC
Submission is supported by the Phase 3 ASTRO study, which achieved the primary endpoint of clinical remiss . . .